Treatment of inflammatory bowel disease has significantlyimproved since the introduction of biologicalagents, such as infliximab, adalimumab, certolizumabpegol,
Hepatocellular carcinoma(HCC),the predominant form of adult liver malignancies,is a global health concern.Its dismal prognosis has prompted recent significant a